VIDEO: Synthetic peptide may yield durable vision gains in retinal diseases

ByPeter K. Kaiser, MD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

In this video from the virtual American Society of Retina Specialists meeting, Peter K. Kaiser, MD, discusses AXT107, a synthetic peptide designed to treat wet age-related macular degeneration and macular edema.

Soon to enter clinical trials, AXT107 (AsclepiX Therapeutics) develops a gel-like depot when injected, which may lead to extended durability.

Published by:

Sources/Disclosures

Collapse

Source: Healio Interviews

Read more about

wet age-related macular degeneration

diabetic macular edema

retinal vein occlusion

retinal disease

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

• Facebook
• Twitter
• LinkedIn
• Email
• Print
• Comment